Tuesday, 07 Apr 2020

You are here

Methotrexate's Low Efficacy in Cutaneous Psoriasis

In a prospective, double-blind, randomized placebo-controlled study, Warren et al. studied the effect of an intensified methotrexate (MTX) in chronic plaque psoriasis and showed MTX to be effective and superior to placebo.  

A total of 120 patients who were MTX-naive adults with active plaque psoriasis patients were randomized to receive 16 weeks of subcutaneous injections of either methotrexate (17.5 mg/wk) or placebo. MTX doses could be escalated to 22.5 mg per week after 8 weeks if patients did not achieve ≥ PASI50% improvement. All patients received folic acid 5 mg per week. 

A PASI 75 response was achieved in 41% of MTX treated but only in 10% of placebo  treated patients (P = 0·0026) by week 16. Subcutaneous methotrexate was generally well tolerated, with no serious adverse events related to this treatment over the 52-week study.

Other analyses and skin biopsies at baseline and week 16 showed MTX clinical effect were mediated by decreases in CD3+ lymphocytes and T helper 17 cell-mediated cytokine transcription.

The authors note that these results are in line with other MTX trials in psoriasis, showing  PASI 75 responses of 36–42% i  3 previous studies using oral methotrexate. Nevertheless, these results are far less than that achieved using biologic therapies, especially the IL-17, IL-23 adn IL-12.23 inhibitors.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

No Cancer Increase in Psoriatic Arthritis or with Biologics in Psoriasis

JAMA Dermatology reports that psoriasis is associated with a slightly increased risk of cancer, particularly keratinocyte cancer and lymphomas.

A systematic review and meta-analysis of 112 studies including more than 2 million patients, also shows no increase in when psoriasis is treated with biologic agents, nor was psoriatic arthritis associated with an increased risk of cancer.   

Bimekizumab Effective in Active Psoriatic Arthritis

Interleukin 17 IIL-17) is important in the pathogenesis of psoriatic disease, with most current approaches targeting IL-17A. Now there is a noveal approach showing that dual neutralisation of IL-17A and IL-17F in psoriatic arthritis arthritis patients results in clinically significant improvement.

Upadacitinib Effective in Phase 3 Psoriatic Arthritis Study

Abbvie has announced top line results of their SELECT-PSA trial of upadacitinib (UPA), wherein both the 15 and 30 mg doses met the primary endpoint of ACR20 response at week 12 and demonstrated radiographic inhibition at week 24.

Which Biologics are Best in Psoriasis

A metanalysis of phase II, III and IV trials in moderate to severe plaque psoriasis suggests comparative efficacy biologic treatments, but that that brodalumab, guselkumab, ixekizumab, and risankizumab-rzaa were shown to have the past skin (PASI) response rates.

Taltz Shines in Non-Radiographic Axial Spondyloarthritis

Ixekizumab (IXE), an interleukin-17A (IL-17A) inhibitor, was recently approved for use in ankylosing spondylitis (also known as radiographic axial spondyloarthritis- axSpA). Lancet has published the results of the COAST-X study showing that ixekizumab was effective in patients with non-radiographic axial spondyloarthritis.